Effector Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
eFFECTOR Therapeutics received a notice of default from Oxford Finance, triggering immediate repayment of all loan obligations.
OTC.Pink
eFFECTOR Therapeutics received notice from Nasdaq that its stock will be delisted due to the company's plans to wind down operations and failure to meet listing requirements.
OTC.Pink
8-K: eFFECTOR Therapeutics Announces Operational Wind-Down, Delisting from Nasdaq, and Leadership Change
eFFECTOR Therapeutics will terminate operations, seek strategic alternatives, delist from Nasdaq, and has appointed a new CEO to manage the wind-down process.
OTC.Pink
eFFECTOR Therapeutics has increased its authorized common stock shares from 40 million to 80 million after a successful vote at its 2024 Annual Meeting of Stockholders.
OTC.Pink
eFFECTOR Therapeutics will collaborate with Dana-Farber Cancer Institute to conduct a Phase 2 trial evaluating zotatifin in combination with other drugs for certain cancers.
OTC.Pink
eFFECTOR Therapeutics has received a notice from Nasdaq for failing to meet the minimum market value requirement for continued listing, giving them until November 12, 2024, to regain compliance.
OTC.Pink
eFFECTOR Therapeutics has entered into a new at-the-market offering agreement for up to $50 million in common stock and terminated a previous agreement.
OTC.Pink
eFFECTOR Therapeutics announced its first quarter 2024 financial results, highlighted by progress in the zotatifin program and a recent $15 million capital raise.
OTC.Pink
eFFECTOR Therapeutics has entered into a new at-the-market offering agreement with H.C. Wainwright & Co., allowing the potential sale of up to $50 million in common stock, while terminating a previous agreement with Cantor Fitzgerald & Co.
OTC.Pink
eFFECTOR Therapeutics reports topline results from a Phase 2 trial of tomivosertib in lung cancer that did not meet its primary endpoint, leading the company to shift focus to its zotatifin program.
OTC.Pink
eFFECTOR Therapeutics reported its Q4 and full year 2023 financial results, highlighted by a $15 million capital raise and upcoming topline data from a key clinical trial.
OTC.Pink
eFFECTOR Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.
OTC.Pink
eFFECTOR Therapeutics has entered into an agreement for a $15 million registered direct offering of common stock and warrants.